All News

A population of patients with relapsed/refractory multiple myeloma appeared to benefit from treatment with selinexor plus daratumumab, bortezomib, and dexamethasone

A population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia appeared to have comparable real-world benefit from tisagenlecleucel compared with findings from the phase 2 ELIANA trial.

Data presented at 2021 ASH indicate that 2-year progression-free survival rates were improved when ibrutinib was added to rituximab plus mini-CHOP in an elderly cohort of patients with previously untreated diffuse large B-cell lymphoma.

Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Depression and anxiety notably impact how patients with hematologic malignancies view clinical studies.

In a population of patients with chronic myeloid leukemia with resistant disease experienced promising activity following treatment with ponatinib regardless of T315I mutation status.

Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.

Patients with autologous stem cell transplant–ineligible relapsed/refractory diffuse large B-cell lymphoma appear to benefit from treatment with tafasitamab and lenalidomide.

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

A strong antibody response was seen in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA COVID-19 vaccine.

Patients with relapsed or refractory follicular lymphoma who had been given 2 or more prior lines of therapy and received tisagenlecleucel saw positive efficacy responses.

Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.

Anti-tumor activity coupled with a manageable safety profile was noted with the combination of ibrutinib plus loncastuximab tesirine for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma at an interim analysis of the LOTIS-3 trial presented at 2021 ASH.

Durable clinical responses were demonstrated with the use of parsaclisib in patients with relapsed or refractory marginal zone lymphoma.

High rates of undetectable minimal residual disease were found in fit patients with chronic lymphocytic leukemia who were treated with venetoclax plus either obinutuzumab or ibrutinib vs chemoimmunotherapy.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Findings from the phase 1b TRIMM-2 study indicated that patients with relapsed/refractory multiple myeloma experienced manageable toxicities and promising responses to treatment with talquetamab and daratumumab.

Ibrutinib and ventoclex given in the frontline setting demonstrated deeper and longer minimal residual disease for elderly and unfit patients with chronic lymphocytic leukemia.

Orca-T improved efficacy outcomes over standard of care therapy for patients with serious hematologic malignancies.

Patients with chronic lymphocytic leukemia who were treated with ibrutinib and venetoclax in the first line continued to demonstrate deep, durable responses with new data showing further benefit to continuous ibrutinib therapy after 2 years.

Research presented at the 63rd ASH Annual Meeting and Exposition found significantly higher MRD-negativity and sustained MRD-negativity rates among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone.

The combination of MRD-guided ibrutinib and venetoclax demonstrated feasibility for treating patients with relapsed/refractory chronic lymphocytic leukemia.

Mosunetuzumab given to patients with heavily pretreated patients with relapsed or refractory follicular lymphoma demonstrated an effective response.

Patients with newly diagnosed multiple myeloma who are non-transplant eligible and intermediate-fit and who received a less toxic regimen of ixazomib, daratumumab, and low-dose dexamethasone demonstrated higher rates of objective response.

Second-line treatment with liscocabtagene maraleucel improved survival compared with the standard of care for patients with relapsed or refractory large B-cell lymphoma.

A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.

Patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival than those who waited and received second-line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma.

Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.

Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.